Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-12-11
2007-12-11
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S002600, C514S012200, C530S350000, C536S023400
Reexamination Certificate
active
11089803
ABSTRACT:
Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
REFERENCES:
patent: 6100071 (2000-08-01), Davis-Smyth
patent: 2005/0175610 (2005-08-01), Wiegand et al.
patent: 2006/0030529 (2006-02-01), Wiegand et al.
patent: 2006/0058234 (2006-03-01), Daly et al.
patent: 2006/0148705 (2006-07-01), Daly et al.
patent: 2006/0172944 (2006-08-01), Wiegand et al.
patent: WO97/44453 (1997-11-01), None
patent: WO98/13071 (1998-04-01), None
patent: WO99/03996 (1999-01-01), None
Herley et al. (1999). Characterization of the VEGF binding site on the Flt-1 receptor. Biochem Biophys Res Commun. 262(3):731-738.
Witmer et al. (2003). Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22(1):1-29.
Terman, B.I., et al, “Identification of a new endothelial cell growth factor receptor tyrosine kinase”, Oncogene (1991) 6:1677-1683.
Terman, B.I., et al., “Identification of teh KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor”, Biochem Biophys Res Comm (1992) 187(3):1579-1586.
Davis-Smyth, T., et al,., 1996, The EMBO Journal 15(18):4919-4927.
Holash, J., et al., (2002) PNAS 99(17):11393-11398.
Heidaran, M.A., et al., (1990) J. Bio. Chem. 265(31):18741-18744.
Cunningham, S.A., et al., (1997) Biochem. Biophys. Res. Comm. 231:596-599.
Fuh, G., et al., (1998) J. Bio. Chem. 273(18):11197-11204.
Wiesmann, C., et al., (1997) Cell 91:695-704.
Barleon, B., et al., (1997) J. Bio. Chem. 272(16):10382-10388.
Davis-Smyth, T., et al., (1998) J. Bio. Chem. 273(6):3216-3222.
Daly Thomas J.
Fandl James P.
Papadopoulos Nicholas J.
Wiegand Stanley J.
Yancopoulos George D.
Gregg, Esq. Valeta
Lockard Jon M
Regeneron Pharmaceuticals Inc.
Saoud Christine J.
LandOfFree
Use of VEGF inhibitors for treatment of eye disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of VEGF inhibitors for treatment of eye disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of VEGF inhibitors for treatment of eye disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3831714